This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (205)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Bruce M. Psaty, MD, PhD; Susan R. Heckbert, MD, PhD; David Atkins, MD, MPH; Rozenn Lemaitre, PhD; Thomas D. Koepsell, MD, MPH; Patricia W. Wahl, PhD; David S. Siscovick, MD, MPH; Edward H. Wagner, MD, MPH

Arch Intern Med. 1994;154(12):1333-1339.

Abstract
Background
While observational studies have suggested that unopposed estrogens reduce the incidence of coronary disease in postmenopausal women, there are few data on the effect of combined therapy with estrogens and progestins—a regimen adopted in recent years to minimize the risk of endometrial hyperplasia and cancer. In clinical trials, the addition of progestins has an adverse effect on serum lipid levels, and these lipid effects have raised the question of whether combined estrogen-progestin therapy increases the risk of coronary disease compared with the use of estrogen alone.

Methods
We conducted a population-based, case-control study among enrollees of Group Health Cooperative of Puget Sound. Cases were postmenopausal women who sustained an incident fatal or nonfatal myocardial infarction in 1986 through 1990. Controls were a stratified random sample of female Group Health Cooperative enrollees frequency matched to the cases by age and calendar year. We reviewed the medical records of the 502 cases and 1193 controls and conducted brief telephone interviews with consenting survivors. The health maintenance organization's computerized pharmacy database was used to ascertain the use of postmenopausal hormones. For the primary analysis of current use, we classified women into one of three groups: (1) nonusers of hormones; (2) users of estrogens alone; or (3) users of combined therapy including both estrogens and progestins. Each group of hormone users was compared with nonusers.

Results
After adjustment for potential confounding factors, the risk ratio of myocardial infarction associated with current use of estrogens alone was 0.69 (95% confidence interval, 0.47 to 1.02); and the risk ratio of myocardial infarction associated with current use of combined therapy was 0.68 (95% confidence interval, 0.38 to 1.22). Duration of combined-therapy use was relatively short, averaging less than 2 years in cases and controls.

Conclusions
In this case-control study, the reduced risk of myocardial infarction associated with the use of estrogens alone was consistent with previous observational studies. Although the 95% confidence interval only excluded a risk above 1.22, the current use of combined therapy was not associated with an adverse effect on the incidence of myocardial infarction in postmenopausal women.

(Arch Intern Med. 1994;154:1333-1339)

Author Affiliations
From the Cardiovascular Health Research Unit, Departments of Medicine (Drs Psaty, Atkins, Koepsell, and Siscovick), Epidemiology (Drs Psaty, Heckbert, Lemaitre, Koepsell, and Siscovick), Biostatistics (Dr Wahl), and Health Services (Drs Psaty, Koepsell, and Wagner), University of Washington, Seattle; and the Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle (Dr Wagner).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
Heckbert et al.
Arch Intern Med 2008;168:826-831.
ABSTRACT | FULL TEXT  

Association of Genetic Variations With Nonfatal Venous Thrombosis in Postmenopausal Women
Smith et al.
JAMA 2007;297:489-498.
ABSTRACT | FULL TEXT  

Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic Variants, and the Risk of Venous Thrombosis in Postmenopausal Women
Smith et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:2807-2812.
ABSTRACT | FULL TEXT  

Risk of New-Onset Atrial Fibrillation in Relation to Body Mass Index
Dublin et al.
Arch Intern Med 2006;166:2322-2328.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and the Cardiovascular System: Lessons Learned and Unanswered Questions
Ouyang et al.
J Am Coll Cardiol 2006;47:1741-1753.
ABSTRACT | FULL TEXT  

Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke.
Lemaitre et al.
Arch Intern Med 2006;166:399-404.
ABSTRACT | FULL TEXT  

Women, hormones, and clinical trials: a beginning, not an end
Miller et al.
J. Appl. Physiol. 2005;99:381-383.
FULL TEXT  

Esterified Estrogens and Conjugated Equine Estrogens and the Risk of Venous Thrombosis
Smith et al.
JAMA 2004;292:1581-1587.
ABSTRACT | FULL TEXT  

Should Progestins Be Blamed for the Failure of Hormone Replacement Therapy to Reduce Cardiovascular Events in Randomized Controlled Trials?
Koh and Sakuma
Arterioscler. Thromb. Vasc. Bio. 2004;24:1171-1179.
ABSTRACT | FULL TEXT  

Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results
Haas et al.
ANN INTERN MED 2004;140:184-188.
ABSTRACT | FULL TEXT  

Issues to debate on the Women's Health Initiative (WHI) study: Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies
Garbe and Suissa
Hum Reprod 2004;19:8-13.
ABSTRACT | FULL TEXT  

Estrogen Therapy and Risk of Cardiovascular Events Among Women With Type 2 Diabetes
Newton et al.
Diabetes Care 2003;26:2810-2816.
ABSTRACT | FULL TEXT  

Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction
Reiner et al.
Blood 2003;102:25-30.
ABSTRACT | FULL TEXT  

In the statin era, how important are intense lifestyle changes?
Parmley
J Am Coll Cardiol 2003;41:273-274.
FULL TEXT  

Influenza Vaccination Is Not Associated with a Reduction in the Risk of Recurrent Coronary Events
Jackson et al.
Am J Epidemiol 2002;156:634-640.
ABSTRACT | FULL TEXT  

Smoking Status and Risk for Recurrent Coronary Events after Myocardial Infarction
Rea et al.
ANN INTERN MED 2002;137:494-500.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease
Humphrey et al.
ANN INTERN MED 2002;137:273-284.
ABSTRACT | FULL TEXT  

Estrogen replacement therapy, atherosclerosis, and vascular function
Mikkola and Clarkson
Cardiovasc Res 2002;53:605-619.
ABSTRACT | FULL TEXT  

Prevention and Treatment of Coronary Heart Disease: Who Benefits?
LaRosa
Circulation 2001;104:1688-1692.
ABSTRACT | FULL TEXT  

Risk of Recurrent Coronary Events in Relation to Use and Recent Initiation of Postmenopausal Hormone Therapy
Heckbert et al.
Arch Intern Med 2001;161:1709-1713.
ABSTRACT | FULL TEXT  

Hormone replacement therapy: where we stand in Europe
Rosano et al.
Eur Heart J 2001;22:439-441.
 

Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Myocardial Infarction in Postmenopausal Women
Psaty et al.
JAMA 2001;285:906-913.
ABSTRACT | FULL TEXT  

Effect of Estrogen Replacement Therapy on Endothelial Function in Peripheral Resistance Arteries in Normotensive and Hypertensive Postmenopausal Women
Higashi et al.
Hypertension 2001;37:651-657.
ABSTRACT | FULL TEXT  

Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women
Rosano et al.
J Am Coll Cardiol 2000;36:2154-2159.
ABSTRACT | FULL TEXT  

The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease
Mosca
Arch Intern Med 2000;160:2263-2272.
ABSTRACT | FULL TEXT  

Use of Calcium Channel Blockers and Risk of Hospitalized Gastrointestinal Tract Bleeding
Kaplan et al.
Arch Intern Med 2000;160:1849-1855.
ABSTRACT | FULL TEXT  

Cholesterol-Lowering Therapy in Secondary Prevention: Remaining Issues
Grundy
J. Clin. Endocrinol. Metab. 2000;85:2092-2098.
FULL TEXT  

Cardiovascular risk in women: the cardiologist's perspective
EDMUNDS and LIP
QJM 2000;93:135-145.
FULL TEXT  

The Risk of Myocardial Infarction Associated with Inhaled beta -Adrenoceptor Agonists
AU et al.
Am. J. Respir. Crit. Care Med. 2000;161:827-830.
ABSTRACT | FULL TEXT  

The HERS Trial Results: Paradigms Lost?
Herrington
ANN INTERN MED 1999;131:463-466.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated With Conservative Surgery and Radiation
Fowble et al.
JCO 1999;17:1680-1680.
ABSTRACT | FULL TEXT  

Does Estrogen Have a Role in the Prevention of Cardiovascular Disease?
Rossouw
J. Clin. Endocrinol. Metab. 1999;84:1806-1810.
FULL TEXT  

Hormone Replacement Therapy, Inflammation, and Hemostasis in Elderly Women
Cushman et al.
Arterioscler. Thromb. Vasc. Bio. 1999;19:893-899.
ABSTRACT | FULL TEXT  

Hormones and Vasoprotection
Oparil
Hypertension 1999;33:170-176.
ABSTRACT | FULL TEXT  

Estradiol Therapy Combined With Progesterone and Endothelium-Dependent Vasodilation in Postmenopausal Women
Gerhard et al.
Circulation 1998;98:1158-1163.
ABSTRACT | FULL TEXT  

Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Hulley et al.
JAMA 1998;280:605-613.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Heart Disease Prevention: Experimentation Trumps Observation
Petitti
JAMA 1998;280:650-652.
FULL TEXT  

Female Sex Hormones and Cardiovascular Disease in Women
Skafar et al.
J. Clin. Endocrinol. Metab. 1997;82:3913-3918.
ABSTRACT | FULL TEXT  

Cardiovascular Disease in Women : A Statement for Healthcare Professionals From the American Heart Association
Mosca et al.
Circulation 1997;96:2468-2482.
FULL TEXT  

Duration of Estrogen Replacement Therapy in Relation to the Risk of Incident Myocardial Infarction in Postmenopausal Women
Heckbert et al.
Arch Intern Med 1997;157:1330-1336.
ABSTRACT  

Sexually Dimorphic Response of the Balloon-Injured Rat Carotid Artery to Hormone Treatment
Oparil et al.
Circulation 1997;95:1301-1307.
ABSTRACT | FULL TEXT  

Medroxyprogesterone Acetate Antagonizes Inhibitory Effects of Conjugated Equine Estrogens on Coronary Artery Atherosclerosis
Adams et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:217-221.
ABSTRACT | FULL TEXT  

Estrogen Replacement
Sullivan
Circulation 1996;94:2699-2702.
FULL TEXT  

Estrogens for Prevention of Coronary Heart Disease: Putting the Brakes on the Bandwagon
Rossouw
Circulation 1996;94:2982-2985.
FULL TEXT  

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Grodstein et al.
NEJM 1996;335:453-461.
ABSTRACT | FULL TEXT  

Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women
Guetta and Cannon
Circulation 1996;93:1928-1937.
FULL TEXT  

Women and coronary heart disease
DTB 1996;34:28-30.
ABSTRACT | FULL TEXT  

Leisure-Time Physical Activity and the Risk of Nonfatal Myocardial Infarction in Postmenopausal Women
Lemaitre et al.
Arch Intern Med 1995;155:2302-2308.
ABSTRACT  

The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies
Psaty et al.
JAMA 1995;274:620-625.
ABSTRACT  

Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
The Writing Group for the PEPI Trial et al.
JAMA 1995;273:199-208.
ABSTRACT  

MORE ON ESTROGEN-PROGESTIN THERAPY AND MI
JWatch General 1994;1994:4-4.
FULL TEXT